Global Bi-Specific Antibodies Therapy Market Analysis and Forecast 2024-2030

Global Bi-Specific Antibodies Therapy Market Analysis and Forecast 2024-2030


Summary

According to APO Research, The global Bi-Specific Antibodies Therapy market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Bi-Specific Antibodies Therapy is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Bi-Specific Antibodies Therapy is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Bi-Specific Antibodies Therapy is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Bi-Specific Antibodies Therapy is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global companies of Bi-Specific Antibodies Therapy include Roche, Amgen, Sanofi, Pfizer, Johnson & Johnson, AstraZeneca, AbbVie, Lindis Biotech and MacroGenics, Inc, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Bi-Specific Antibodies Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Bi-Specific Antibodies Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Bi-Specific Antibodies Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Bi-Specific Antibodies Therapy revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Bi-Specific Antibodies Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Bi-Specific Antibodies Therapy revenue, projected growth trends, production technology, application and end-user industry.

Bi-Specific Antibodies Therapy segment by Company

Roche
Amgen
Sanofi
Pfizer
Johnson & Johnson
AstraZeneca
AbbVie
Lindis Biotech
MacroGenics, Inc
Genmab
Alphamab Co. Ltd
Akeso, Inc.
Bi-Specific Antibodies Therapy segment by Type

Fragment-Based Antibodies
IgG-Based Antibodies
Bi-Specific Antibodies Therapy segment by Application

Cancer
Haemophilia
Other Non-Cancer Diseases
Bi-Specific Antibodies Therapy segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bi-Specific Antibodies Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Bi-Specific Antibodies Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bi-Specific Antibodies Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Bi-Specific Antibodies Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Bi-Specific Antibodies Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Bi-Specific Antibodies Therapy revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.


1 Market Overview
1.1 Product Definition
1.2 Bi-Specific Antibodies Therapy Market by Type
1.2.1 Global Bi-Specific Antibodies Therapy Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Fragment-Based Antibodies
1.2.3 IgG-Based Antibodies
1.3 Bi-Specific Antibodies Therapy Market by Application
1.3.1 Global Bi-Specific Antibodies Therapy Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Cancer
1.3.3 Haemophilia
1.3.4 Other Non-Cancer Diseases
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Bi-Specific Antibodies Therapy Market Dynamics
2.1 Bi-Specific Antibodies Therapy Industry Trends
2.2 Bi-Specific Antibodies Therapy Industry Drivers
2.3 Bi-Specific Antibodies Therapy Industry Opportunities and Challenges
2.4 Bi-Specific Antibodies Therapy Industry Restraints
3 Global Growth Perspective
3.1 Global Bi-Specific Antibodies Therapy Market Perspective (2019-2030)
3.2 Global Bi-Specific Antibodies Therapy Growth Trends by Region
3.2.1 Global Bi-Specific Antibodies Therapy Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Bi-Specific Antibodies Therapy Market Size by Region (2019-2024)
3.2.3 Global Bi-Specific Antibodies Therapy Market Size by Region (2025-2030)
4 Competitive Landscape by Players
4.1 Global Bi-Specific Antibodies Therapy Revenue by Players
4.1.1 Global Bi-Specific Antibodies Therapy Revenue by Players (2019-2024)
4.1.2 Global Bi-Specific Antibodies Therapy Revenue Market Share by Players (2019-2024)
4.1.3 Global Bi-Specific Antibodies Therapy Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Bi-Specific Antibodies Therapy Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Bi-Specific Antibodies Therapy Key Players Headquarters & Area Served
4.4 Global Bi-Specific Antibodies Therapy Players, Product Type & Application
4.5 Global Bi-Specific Antibodies Therapy Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Bi-Specific Antibodies Therapy Market CR5 and HHI
4.6.2 Global Top 5 and 10 Bi-Specific Antibodies Therapy Players Market Share by Revenue in 2023
4.6.3 2023 Bi-Specific Antibodies Therapy Tier 1, Tier 2, and Tier 3
5 Bi-Specific Antibodies Therapy Market Size by Type
5.1 Global Bi-Specific Antibodies Therapy Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Bi-Specific Antibodies Therapy Revenue by Type (2019-2030)
5.3 Global Bi-Specific Antibodies Therapy Revenue Market Share by Type (2019-2030)
6 Bi-Specific Antibodies Therapy Market Size by Application
6.1 Global Bi-Specific Antibodies Therapy Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Bi-Specific Antibodies Therapy Revenue by Application (2019-2030)
6.3 Global Bi-Specific Antibodies Therapy Revenue Market Share by Application (2019-2030)
7 Company Profiles
7.1 Roche
7.1.1 Roche Comapny Information
7.1.2 Roche Business Overview
7.1.3 Roche Bi-Specific Antibodies Therapy Revenue and Gross Margin (2019-2024)
7.1.4 Roche Bi-Specific Antibodies Therapy Product Portfolio
7.1.5 Roche Recent Developments
7.2 Amgen
7.2.1 Amgen Comapny Information
7.2.2 Amgen Business Overview
7.2.3 Amgen Bi-Specific Antibodies Therapy Revenue and Gross Margin (2019-2024)
7.2.4 Amgen Bi-Specific Antibodies Therapy Product Portfolio
7.2.5 Amgen Recent Developments
7.3 Sanofi
7.3.1 Sanofi Comapny Information
7.3.2 Sanofi Business Overview
7.3.3 Sanofi Bi-Specific Antibodies Therapy Revenue and Gross Margin (2019-2024)
7.3.4 Sanofi Bi-Specific Antibodies Therapy Product Portfolio
7.3.5 Sanofi Recent Developments
7.4 Pfizer
7.4.1 Pfizer Comapny Information
7.4.2 Pfizer Business Overview
7.4.3 Pfizer Bi-Specific Antibodies Therapy Revenue and Gross Margin (2019-2024)
7.4.4 Pfizer Bi-Specific Antibodies Therapy Product Portfolio
7.4.5 Pfizer Recent Developments
7.5 Johnson & Johnson
7.5.1 Johnson & Johnson Comapny Information
7.5.2 Johnson & Johnson Business Overview
7.5.3 Johnson & Johnson Bi-Specific Antibodies Therapy Revenue and Gross Margin (2019-2024)
7.5.4 Johnson & Johnson Bi-Specific Antibodies Therapy Product Portfolio
7.5.5 Johnson & Johnson Recent Developments
7.6 AstraZeneca
7.6.1 AstraZeneca Comapny Information
7.6.2 AstraZeneca Business Overview
7.6.3 AstraZeneca Bi-Specific Antibodies Therapy Revenue and Gross Margin (2019-2024)
7.6.4 AstraZeneca Bi-Specific Antibodies Therapy Product Portfolio
7.6.5 AstraZeneca Recent Developments
7.7 AbbVie
7.7.1 AbbVie Comapny Information
7.7.2 AbbVie Business Overview
7.7.3 AbbVie Bi-Specific Antibodies Therapy Revenue and Gross Margin (2019-2024)
7.7.4 AbbVie Bi-Specific Antibodies Therapy Product Portfolio
7.7.5 AbbVie Recent Developments
7.8 Lindis Biotech
7.8.1 Lindis Biotech Comapny Information
7.8.2 Lindis Biotech Business Overview
7.8.3 Lindis Biotech Bi-Specific Antibodies Therapy Revenue and Gross Margin (2019-2024)
7.8.4 Lindis Biotech Bi-Specific Antibodies Therapy Product Portfolio
7.8.5 Lindis Biotech Recent Developments
7.9 MacroGenics, Inc
7.9.1 MacroGenics, Inc Comapny Information
7.9.2 MacroGenics, Inc Business Overview
7.9.3 MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue and Gross Margin (2019-2024)
7.9.4 MacroGenics, Inc Bi-Specific Antibodies Therapy Product Portfolio
7.9.5 MacroGenics, Inc Recent Developments
7.10 Genmab
7.10.1 Genmab Comapny Information
7.10.2 Genmab Business Overview
7.10.3 Genmab Bi-Specific Antibodies Therapy Revenue and Gross Margin (2019-2024)
7.10.4 Genmab Bi-Specific Antibodies Therapy Product Portfolio
7.10.5 Genmab Recent Developments
7.11 Alphamab Co. Ltd
7.11.1 Alphamab Co. Ltd Comapny Information
7.11.2 Alphamab Co. Ltd Business Overview
7.11.3 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue and Gross Margin (2019-2024)
7.11.4 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Product Portfolio
7.11.5 Alphamab Co. Ltd Recent Developments
7.12 Akeso, Inc.
7.12.1 Akeso, Inc. Comapny Information
7.12.2 Akeso, Inc. Business Overview
7.12.3 Akeso, Inc. Bi-Specific Antibodies Therapy Revenue and Gross Margin (2019-2024)
7.12.4 Akeso, Inc. Bi-Specific Antibodies Therapy Product Portfolio
7.12.5 Akeso, Inc. Recent Developments
8 North America
8.1 North America Bi-Specific Antibodies Therapy Revenue (2019-2030)
8.2 North America Bi-Specific Antibodies Therapy Revenue by Type (2019-2030)
8.2.1 North America Bi-Specific Antibodies Therapy Revenue by Type (2019-2024)
8.2.2 North America Bi-Specific Antibodies Therapy Revenue by Type (2025-2030)
8.3 North America Bi-Specific Antibodies Therapy Revenue Share by Type (2019-2030)
8.4 North America Bi-Specific Antibodies Therapy Revenue by Application (2019-2030)
8.4.1 North America Bi-Specific Antibodies Therapy Revenue by Application (2019-2024)
8.4.2 North America Bi-Specific Antibodies Therapy Revenue by Application (2025-2030)
8.5 North America Bi-Specific Antibodies Therapy Revenue Share by Application (2019-2030)
8.6 North America Bi-Specific Antibodies Therapy Revenue by Country
8.6.1 North America Bi-Specific Antibodies Therapy Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Bi-Specific Antibodies Therapy Revenue by Country (2019-2024)
8.6.3 North America Bi-Specific Antibodies Therapy Revenue by Country (2025-2030)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Bi-Specific Antibodies Therapy Revenue (2019-2030)
9.2 Europe Bi-Specific Antibodies Therapy Revenue by Type (2019-2030)
9.2.1 Europe Bi-Specific Antibodies Therapy Revenue by Type (2019-2024)
9.2.2 Europe Bi-Specific Antibodies Therapy Revenue by Type (2025-2030)
9.3 Europe Bi-Specific Antibodies Therapy Revenue Share by Type (2019-2030)
9.4 Europe Bi-Specific Antibodies Therapy Revenue by Application (2019-2030)
9.4.1 Europe Bi-Specific Antibodies Therapy Revenue by Application (2019-2024)
9.4.2 Europe Bi-Specific Antibodies Therapy Revenue by Application (2025-2030)
9.5 Europe Bi-Specific Antibodies Therapy Revenue Share by Application (2019-2030)
9.6 Europe Bi-Specific Antibodies Therapy Revenue by Country
9.6.1 Europe Bi-Specific Antibodies Therapy Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Bi-Specific Antibodies Therapy Revenue by Country (2019-2024)
9.6.3 Europe Bi-Specific Antibodies Therapy Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
9.6.9 Nordic Countries
10 China
10.1 China Bi-Specific Antibodies Therapy Revenue (2019-2030)
10.2 China Bi-Specific Antibodies Therapy Revenue by Type (2019-2030)
10.2.1 China Bi-Specific Antibodies Therapy Revenue by Type (2019-2024)
10.2.2 China Bi-Specific Antibodies Therapy Revenue by Type (2025-2030)
10.3 China Bi-Specific Antibodies Therapy Revenue Share by Type (2019-2030)
10.4 China Bi-Specific Antibodies Therapy Revenue by Application (2019-2030)
10.4.1 China Bi-Specific Antibodies Therapy Revenue by Application (2019-2024)
10.4.2 China Bi-Specific Antibodies Therapy Revenue by Application (2025-2030)
10.5 China Bi-Specific Antibodies Therapy Revenue Share by Application (2019-2030)
11 Asia (Excluding China)
11.1 Asia Bi-Specific Antibodies Therapy Revenue (2019-2030)
11.2 Asia Bi-Specific Antibodies Therapy Revenue by Type (2019-2030)
11.2.1 Asia Bi-Specific Antibodies Therapy Revenue by Type (2019-2024)
11.2.2 Asia Bi-Specific Antibodies Therapy Revenue by Type (2025-2030)
11.3 Asia Bi-Specific Antibodies Therapy Revenue Share by Type (2019-2030)
11.4 Asia Bi-Specific Antibodies Therapy Revenue by Application (2019-2030)
11.4.1 Asia Bi-Specific Antibodies Therapy Revenue by Application (2019-2024)
11.4.2 Asia Bi-Specific Antibodies Therapy Revenue by Application (2025-2030)
11.5 Asia Bi-Specific Antibodies Therapy Revenue Share by Application (2019-2030)
11.6 Asia Bi-Specific Antibodies Therapy Revenue by Country
11.6.1 Asia Bi-Specific Antibodies Therapy Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Bi-Specific Antibodies Therapy Revenue by Country (2019-2024)
11.6.3 Asia Bi-Specific Antibodies Therapy Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 Middle East, Africa, Latin America
12.1 MEALA Bi-Specific Antibodies Therapy Revenue (2019-2030)
12.2 MEALA Bi-Specific Antibodies Therapy Revenue by Type (2019-2030)
12.2.1 MEALA Bi-Specific Antibodies Therapy Revenue by Type (2019-2024)
12.2.2 MEALA Bi-Specific Antibodies Therapy Revenue by Type (2025-2030)
12.3 MEALA Bi-Specific Antibodies Therapy Revenue Share by Type (2019-2030)
12.4 MEALA Bi-Specific Antibodies Therapy Revenue by Application (2019-2030)
12.4.1 MEALA Bi-Specific Antibodies Therapy Revenue by Application (2019-2024)
12.4.2 MEALA Bi-Specific Antibodies Therapy Revenue by Application (2025-2030)
12.5 MEALA Bi-Specific Antibodies Therapy Revenue Share by Application (2019-2030)
12.6 MEALA Bi-Specific Antibodies Therapy Revenue by Country
12.6.1 MEALA Bi-Specific Antibodies Therapy Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Bi-Specific Antibodies Therapy Revenue by Country (2019-2024)
12.6.3 MEALA Bi-Specific Antibodies Therapy Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings